2022
DOI: 10.1016/j.msard.2022.104212
|View full text |Cite
|
Sign up to set email alerts
|

AQP4-IgG-positive neuromyelitis optica spectrum disorder and temporally detected neoplasms: case report and systematic review

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4

Citation Types

1
4
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 6 publications
(6 citation statements)
references
References 75 publications
1
4
0
Order By: Relevance
“…The authors clearly demonstrated the presence of AQP-4 IgG in serum and the expression of AQP-4 in tumor tissue and indicated that this was likely the trigger of an autoimmune response. In 59.7% to 61.0% of all paraneoplastic NMOSD cases, NMOSD-related symptoms either preceded or occurred concurrently with cancer diagnosis, similar to that observed in the present case [ 3 , 16 , 19 ]. The most common initial presentation of paraneoplastic NMOSD was transverse myelitis; however, among patients with central nervous system symptoms, APS accounted for 83.3% [ 3 ].…”
Section: Discussionsupporting
confidence: 87%
See 3 more Smart Citations
“…The authors clearly demonstrated the presence of AQP-4 IgG in serum and the expression of AQP-4 in tumor tissue and indicated that this was likely the trigger of an autoimmune response. In 59.7% to 61.0% of all paraneoplastic NMOSD cases, NMOSD-related symptoms either preceded or occurred concurrently with cancer diagnosis, similar to that observed in the present case [ 3 , 16 , 19 ]. The most common initial presentation of paraneoplastic NMOSD was transverse myelitis; however, among patients with central nervous system symptoms, APS accounted for 83.3% [ 3 ].…”
Section: Discussionsupporting
confidence: 87%
“…Although NMOSD is primarily an idiopathic autoimmune disease, it also occurs as a paraneoplastic syndrome in 1.3% to 25% of patients [ 3 , 14 16 ]. Those with paraneoplastic NMOSD are generally older at disease onset (mean age, 50–55 years) [ 3 , 14 17 ], while the overall median age of onset for NMOSD ranges between 32 and 41 years.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…The following are available online at : Supplementary Material S1: PRISMA 2020 Checklist [ 54 ]; Supplementary Material S2: List of Excluded Studies [ 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 ].…”
mentioning
confidence: 99%